Rapamycin and Alzheimer's Disease: Time for a Clinical Trial?

Table of Contents

• Key Points
• The Growing Burden of Alzheimer's Disease
• What Is Rapamycin and How Does It Work?
• Preclinical Evidence: What Animal Studies Show
• The Astonishing Gap: No Clinical Trials Yet
• Fear of Failure: A Barrier to Progress
• The "Mouse Models Aren't Perfect" Argument
• Rapamycin's Reputation: Are the Side Effects Acceptable?
• What Dose Would Be Used?
• Can Rapamycin Reach the Brain?
• When Should Treatment Start?
• The Generic Drug Problem
• The Case for Action
• Frequently Asked Questions
• Source Information

Key Points

• Rapamycin is FDA-approved for organ transplant, and it slows aging in mice, but no clinical trial has tested it in Alzheimer’s patients.
• In seven Alzheimer’s mouse models, rapamycin reduced amyloid and tau pathology, preserved blood vessels, prevented neuron loss, and improved cognitive function.
• Side effects like mouth sores and lipid changes are dose-dependent and reversible; older adults taking rapamycin alone had mild side effects without serious adverse events.
• Oral rapamycin reaches brain tissue in humans, with pharmacologically relevant concentrations found in brain tumors in all 14 patients studied in one trial.
• Lack of clinical trials likely stems from fear of failure and poor financial incentives for generic rapamycin, not from lack of promising evidence.

The Growing Burden of Alzheimer's Disease

Alzheimer's disease (AD) and other dementias represent an increasingly heavy burden on societies worldwide. Currently, an estimated 5.4 million Americans live with Alzheimer's disease, and for each of these individuals, one to four family members typically serve as caregivers. This burden extends far beyond the patients themselves, affecting families, healthcare systems, and national economies.

The statistics are sobering. As the population ages, the number of affected individuals is expected to reach 13.8 million in the United States by mid-century unless effective therapies are developed and implemented. Age remains the single greatest risk factor for Alzheimer's disease, with the risk of developing the disease estimated to double every 5 years after age 65. Even more striking, the risk of death from Alzheimer's disease increases approximately 700-fold between the ages of 55 and 85. The combination of a growing elderly population and escalating age-related risk has led some experts to predict that Alzheimer's disease will "break Medicare" in the United States and overwhelm the healthcare economies of many other countries.

Currently, there are no effective treatments available to delay or prevent the onset and progression of Alzheimer's disease, despite significant investments in research dollars. In fact, more than half of the annual research budget of the National Institute on Aging (NIA) has been earmarked for Alzheimer's research for several years now.

Why has progress been so limited? Several factors likely contribute, including the still poorly understood molecular mechanisms of disease pathogenesis and the limited ability to predict disease onset at early stages when intervention might be most effective. However, the authors of this paper speculate that an additional major barrier — possibly the most important one — is the lack of attention paid to the role of the aging process itself as a critical factor in Alzheimer's disease.

Over the past two decades, research on the biology of aging — a field called geroscience — has made substantial progress in understanding the genetic, molecular, and biochemical mechanisms of aging. Researchers have identified a small number of "hallmarks of aging" — processes driven by genes that regulate aging and that play important roles in the decline in function and increase in disease associated with old age. By targeting these aging-regulating genes and the molecular processes they represent, scientists have been able to increase life span and delay age-associated decline in every laboratory animal where this has been attempted. In principle, targeting these same processes should also be effective at delaying the onset of specific age-related diseases, including Alzheimer's disease, and, in some cases, even reversing specific disease-related pathologies.

What Is Rapamycin and How Does It Work?

Rapamycin is currently the most effective and reproducible pharmacological approach for directly targeting the aging process to increase life span and health span in laboratory animals. The drug works by inhibiting an enzyme called the mechanistic target of rapamycin (mTOR), which acts as a nutrient and growth factor-responsive kinase — essentially a cellular sensor that regulates growth and metabolism.

Inside cells, rapamycin binds to a protein called FK506 binding protein 12 (FKBP12), and this complex then inhibits the activity of mTOR complex 1 (mTORC1). Because mTORC1 plays a central role in regulating growth and metabolism, rapamycin has complex, context-dependent effects on cells, including potential inhibition of mRNA translation, induction of autophagy (the cell's self-cleaning process), and altered mitochondrial metabolism. Chronic treatment with rapamycin can also indirectly inhibit a related complex called mTOR complex 2 (mTORC2). These complicated cellular interactions help explain the wide-ranging effects of the drug.

Preclinical Evidence: What Animal Studies Show

The evidence that rapamycin can extend life span is impressive. Rapamycin increases life span by 10 to 30% in multiple strains of mice when started either early or late in life, and whether administered continuously, intermittently, or transiently. Notably, a single 3-month treatment regimen was recently shown to increase remaining life expectancy of mice by up to 60%.

But rapamycin does more than extend life span — it also delays, or even reverses, nearly every age-related disease or decline in function in which it has been tested in mice, rats, and companion dogs. This includes:

• Cancers
• Cardiac dysfunction
• Kidney disease
• Obesity
• Cognitive decline
• Periodontal disease
• Macular degeneration
• Muscle loss
• Stem cell function decline
• Immune senescence (aging of the immune system)

When it comes to Alzheimer's disease specifically, rapamycin has shown beneficial effects in several different mouse models of the disease. These models include those exhibiting amyloidosis alone (accumulation of amyloid-beta protein), amyloidosis plus tauopathy (abnormal tau protein accumulation), or primary tauopathy alone. The breadth and depth of positive preclinical data for rapamycin is perhaps greater than for any other potential Alzheimer's therapy at this time.

Specifically, rapamycin has been shown to:

• Reduce amyloid-β (Aβ) deposition — the sticky plaques that accumulate in Alzheimer's brains
• Reduce pathogenic tau phosphorylation and the abundance of misfolded tau species, including neurofibrillary tangles
• Restore cerebral blood flow and cerebromicrovascular density (the density of small blood vessels in the brain)
• Preserve blood-brain barrier integrity — the protective barrier that shields the brain
• Prevent human tau-induced neuronal loss — protecting brain cells from dying
• Improve cognitive function — better memory and learning in animal models

These beneficial outcomes have been observed in seven different mouse models of Alzheimer's disease, including:

• 3× transgenic mice
• P301S mice
• hAPP(J20) mice
• Transgenic 2576 mice
• APP/PS1 mice
• ApoE4 transgenic mice
• A viral vector-based mouse model expressing tau P301L in the lateral entorhinal cortex

Importantly, improvements have been observed when rapamycin treatment was initiated either before the onset of disease symptoms or after symptoms and pathology were already present — suggesting the drug might help even in later stages.

Additional studies support these findings. Genetic inhibition of mTOR has been shown to rescue memory deficits, improve cognitive function, and decrease tau and Aβ deposits in animal models. The rapamycin derivative temsirolimus has also been shown to improve spatial learning and memory and prevent apoptosis (cell death) in the hippocampus of Alzheimer's mouse models.

The Astonishing Gap: No Clinical Trials Yet

Given this large body of evidence, one might expect that rapamycin would be a leading candidate for clinical trials in Alzheimer's patients. After all, rapamycin is already a FDA-approved drug with known dosing and side effect profiles, having been used for decades in organ transplant patients. Yet, to the best of the authors' knowledge, no clinical trial has been proposed or initiated to test rapamycin's efficacy in Alzheimer's patients or in patients with mild cognitive impairment (MCI).

Even more surprising, there hasn't even been an analysis of whether organ transplant patients taking rapamycin are at a reduced risk of developing Alzheimer's disease. A recent search of the National Institutes of Health (NIH) clinical trials database at clinicaltrials.gov using the search terms "Alzheimer Disease" (as a condition or disease) and "rapamycin" (as another term) yielded no results at all.

Fear of Failure: A Barrier to Progress

Why has this promising drug been overlooked for Alzheimer's clinical trials? To understand this, the authors contacted several colleagues in both academia and industry and posed this very question. The array of reasons they received was both surprising and enlightening. These reasons can be grouped into two categories: those that apply to any Alzheimer's clinical trial and those specific to rapamycin.

The first category can be summarized essentially as "fear of failure." Clinical trials are expensive and time-consuming. Alzheimer's clinical trials may be particularly difficult to interpret, and there is a perception that many Alzheimer's trials have already failed, resulting in wasted resources. The unstated implication seems to be that we should not undertake any new clinical trial for Alzheimer's disease unless we know for sure it will be successful.

But this logic is fundamentally flawed, the authors argue. It is impossible to know whether a properly designed clinical trial will succeed at the outset. Subscribing to this line of reasoning means accepting that we should not perform any clinical trials for Alzheimer's at all, which would ensure no development of new therapies — a position that is simply not acceptable given the severity of the disease.

The authors note that NIH funding, congressional mandates, and foundation funding for Alzheimer's research all come with the expectation that potential therapies will be developed and tested when there is a reasonable probability they could improve patients' health and well-being. They are not arguing that additional resources should not be put toward basic and preclinical research — indeed, they emphasize that the development of predictive biomarkers suitable for shorter proof-of-concept clinical trials would greatly accelerate testing of potential therapies. However, the idea that we should forego all clinical trials for Alzheimer's because past trials have failed "is simply not a reasonable proposition and must be rejected."

The "Mouse Models Aren't Perfect" Argument

Related to this fear of failure is another argument: that preclinical studies in mice should not be used to guide clinical development of Alzheimer's therapies, largely because none of the mouse models of Alzheimer's accurately capture the full spectrum of the disease as it appears in patients. By this reasoning, demonstrating efficacy in a mouse model is not strong enough evidence to move forward into clinical testing.

While this logic is debatable, the authors point out that it's important to consider the larger body of data for rapamycin. Rapamycin and other methods of inhibiting mTORC1 are effective not in just one mouse model, but in:

• Four different well-established mouse models of Alzheimer's amyloidopathy
• Two mouse models of primary tauopathy
• One model of combined amyloidopathy and tauopathy

Furthermore, rapamycin blocks or ameliorates the majority of Alzheimer's-relevant pathologies in mouse models and also restores cognitive function. There is substantial evidence that the mTOR signaling pathway — the target of rapamycin — is perturbed in brain tissue from Alzheimer's patients as well as in animal models of the disease, providing evidence for common biological pathways underpinning rapamycin's efficacy.

Perhaps most importantly, mTOR is a central regulator of the greatest risk factor for Alzheimer's disease: aging itself. Inhibition of mTOR by rapamycin effectively delays aging and reverses age-associated functional decline in mice. It also appears to ameliorate functional deficits of the aged heart in dogs and improves immune responses in older people.

Rapamycin's Reputation: Are the Side Effects Acceptable?

Aside from fear of failure, several misperceptions may have limited consideration of rapamycin as a potential clinical intervention for Alzheimer's disease. There is no question that side effects have been associated with the use of rapamycin and other mTOR inhibitors in patients. The most common include:

• Mouth sores (similar to canker sores)
• Increase in blood lipids (cholesterol and triglycerides)
• Impaired wound healing
• Gastrointestinal discomfort
• Potential for increased risk of infection

However, it's crucial to understand the context: these side effects have largely been observed in patients who received organ transplants or are being treated for cancer — patients who are often simultaneously taking other medications and who typically receive relatively high doses. Moreover, the side effects associated with rapamycin are dose-dependent and reversible, meaning it should be fairly straightforward to establish safe dosing guidelines for an Alzheimer's clinical trial, which might include intermittent administration.

The authors emphasize that there are actually few data on adverse events associated with rapamycin monotherapy (use of rapamycin alone) in older individuals. What data exists is encouraging:

Study 1 (healthy older adults): A recent clinical trial reported relatively mild side effects and no negative impact on the immune system, nor changes in blood glucose, insulin secretion, or insulin sensitivity, in healthy 70- to 95-year-old individuals given rapamycin for at least 8 weeks.

Study 2 (RAD001, a rapamycin derivative): Another study reported mild side effects associated with 6 weeks of treatment of healthy elderly people with the rapamycin-derivative RAD001. This study documented improved, not impaired, immune function. At the highest dose tested (20 mg/week), the most common side effects were:

• Mouth ulcers: 17% of participants
• Headache: 17%
• Fatigue: 7.5%
• Neutropenia (low white blood cell count): 6%

Notably, all side effects were reduced at a lower dose (5 mg/week) that was actually more effective at boosting an immune response to the flu vaccine. The participants in these studies were only on the drug for 6 to 16 weeks, but it is significant that there were no serious adverse events attributed to the treatment in either study — providing evidence that rapamycin is well tolerated as a monotherapy in elderly people.

Even taking the unlikely worst-case scenario — that side effects in Alzheimer's patients would be comparable to those experienced by organ transplant and cancer patients — the authors argue that such side effects would be acceptable if Alzheimer's disease progression could be attenuated. Many people tolerate high-dose rapamycin therapy for years with little, if any, discomfort. Indeed, a recent study indicates that less than 5% of patients with lymphangioleiomyomatosis (a rare lung disease) taking rapamycin reported side effects after 1 year of continuous treatment; of those who did report side effects, they were relatively mild, consisting primarily of mouth sores, nausea, and diarrhea. The authors conclude that most Alzheimer's patients, their caregivers, and family members would likely tolerate this level of risk and inconvenience for a chance at delaying disease progression.

What Dose Would Be Used?

One argument against moving forward is that we don't know the right dose of rapamycin to test in an Alzheimer's clinical trial. While it's true that clinical data on the most effective dose for combating Alzheimer's (if any dose is effective) is lacking, there are abundant clinical data on biological efficacy and side effects of rapamycin and rapamycin derivatives for other indications. Given the long history of rapamycin use to prevent organ transplant rejection, along with the studies in healthy elderly people discussed above, the authors argue it seems reasonable to consider testing doses of rapamycin used in these different studies.

Can Rapamycin Reach the Brain?

One legitimate scientific question is whether rapamycin can effectively cross the blood-brain barrier — the protective membrane that prevents many substances from entering the brain. Although rapamycin concentrations that were efficacious have been demonstrated in the brains of Alzheimer's mice, there are limited data regarding how efficiently rapamycin crosses the blood-brain barrier in humans.

However, at least one study has shown that oral delivery of rapamycin led to pharmacologically relevant concentrations of the drug detectable in brain tumors in 14 of 14 patients. Thus, rapamycin is clearly able to cross the blood-brain barrier in people to some extent, and some rapamycin derivatives may be even more effective in this regard. The authors also note that delivery of rapamycin to the brain may be further facilitated by blood-brain barrier breakdown associated with aging — a condition that is common in older adults. In addition, numerous studies in mice have confirmed that rapamycin effectively inhibits mTOR signaling in the brain and has substantial effects on brain physiology.

When Should Treatment Start?

It's possible that rapamycin might only be effective at delaying Alzheimer's if treatment is started before the disease has progressed to the point of clinical diagnosis. However, at least a subset of preclinical studies reported positive effects of rapamycin in mouse models even after substantial Alzheimer's-like cognitive deficits and histopathology were already present.

These observations, combined with rapamycin's ability to improve function in other tissues — most notably the cardiac and immune systems — raise the possibility that cognitive function could be improved in patients with early- or moderate-stage Alzheimer's even after substantial cognitive decline. The authors recommend clinical trials for rapamycin efficacy in two groups:

1. Patients with mild cognitive impairment (MCI) who are likely to progress to a diagnosis of Alzheimer's disease
2. Patients recently diagnosed with Alzheimer's disease

The Generic Drug Problem

Finally, the authors address an uncomfortable reality: the fact that rapamycin is off-patent and available as a generic medication may have played a major role in the lack of clinical testing for efficacy against Alzheimer's disease. Simply put, there is little incentive for large pharmaceutical companies to invest in its development and testing because they would not be able to recoup their investment through exclusive sales.

The authors argue, however, that the lack of a strong profit motive should not preclude testing by the NIH or through federally or privately funded investigators. It remains unclear why this has not yet happened — a question that deserves serious public attention.

The Case for Action

In conclusion, the evidence is compelling. Despite robust preclinical evidence that rapamycin may be effective at slowing Alzheimer's disease progression, there has not yet been a single clinical trial to test this potentially transforming hypothesis. A number of studies have shown benefits from rapamycin in the context of normative aging and robust protection in a subset of animal models of Alzheimer's disease.

Rapamycin has been used extensively in the clinic, with well-understood dosing and safety information. It and other mTOR inhibitors appear to be well tolerated in elderly subjects, with limited side effects that are reversible, dose-dependent, and would be acceptable for an Alzheimer's therapy. The authors therefore argue strongly for the initiation of clinical trials to test rapamycin as a drug to delay disease progression in Alzheimer's patients as soon as possible.

This argument has only grown more urgent in the years since this article was published. With the aging population and the continuing lack of disease-modifying treatments for Alzheimer's, repurposing existing drugs like rapamycin represents a potentially faster and more cost-effective path to treatment than developing entirely new medications from scratch. The call for clinical trials is not just a scientific recommendation — it is a matter of public health urgency.

Frequently Asked Questions

What is rapamycin and how does it work?

Rapamycin is an FDA-approved drug used in organ transplant patients. It inhibits an enzyme called mTOR, which regulates cell growth and metabolism. In laboratory animals, it extends life span by 10 to 30 percent and delays many age-related diseases. It has not been tested in Alzheimer’s patients, despite strong animal evidence.

Has rapamycin been tested in humans with Alzheimer's disease?

No. According to the article, no clinical trial has been proposed or initiated to test rapamycin in people with Alzheimer’s disease or mild cognitive impairment. Even a search of the NIH clinical trials database found no results when combining Alzheimer’s disease and rapamycin.

What do animal studies show about rapamycin and Alzheimer's?

In seven different mouse models of Alzheimer’s, rapamycin reduced amyloid plaques, decreased abnormal tau, restored blood flow, preserved the blood-brain barrier, prevented neuron loss, and improved memory. Some improvements occurred even when treatment began after symptoms were present. These results suggest possible benefit, but human trials are needed.

What side effects can rapamycin cause?

Common side effects seen in transplant or cancer patients include mouth sores, increased blood lipids, impaired wound healing, stomach discomfort, and higher infection risk. These side effects are dose-dependent and reversible. In healthy older adults taking rapamycin alone, side effects were mild, with no serious adverse events reported.

Is rapamycin safe for older people?

Two short studies in healthy elderly people suggest it is reasonably well tolerated. One study in adults aged 70 to 95 found mild side effects and no negative immune effects. Another in older adults using a rapamycin derivative reported improved immune response and mild side effects like mouth ulcers and headache, with no serious events attributed to treatment.

Can rapamycin reach the brain?

Yes. In humans, oral rapamycin produced drug concentrations in brain tumors in 14 of 14 patients in one study, showing it crosses the blood-brain barrier. Animal studies confirm rapamycin inhibits mTOR signaling in the brain and affects brain function. Aging-related blood-brain barrier breakdown may further increase brain exposure in older adults.

Why hasn't rapamycin been tested in Alzheimer's clinical trials?

The authors cite fear of failure, concerns that mouse models don’t fully represent human disease, and the fact that rapamycin is a generic drug with little profit incentive for pharmaceutical companies. They argue these reasons are not scientifically justified, given strong animal data and the urgent need for Alzheimer’s treatments.

When should a patient with Alzheimer's disease seek a second opinion about rapamycin as a possible treatment?

A second opinion is worthwhile if your doctor says there are no effective treatments for Alzheimer's disease. In animal models, rapamycin has been shown to reduce amyloid plaques, tau tangles, and cognitive decline, but no clinical trials have yet tested this drug in Alzheimer's patients. Therefore, rapamycin is not currently a standard option. A second opinion can clarify the strength of this evidence, discuss whether clinical trial participation might be appropriate, and review potential side effects like mouth sores or elevated cholesterol. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article title: Rapamycin and Alzheimer’s disease- Time for a clinical trial?

Journal: Science Translational Medicine, Volume 11, Issue 476, January 23, 2019. doi:10.1126/scitranslmed.aar4289

Disclosures: M.K. serves on the Scientific Advisory Board of resTORbio Inc. V.G. is an inventor on U.S. patent applications 13/128,800, 14/435,306, and 61/790,485 regarding the use of encapsulated rapamycin for treating a variety of conditions; V.G. also consults for Rapamycin Holdings Inc.

Funding: The authors were supported by the University of Washington and UT Health San Antonio Nathan Shock Centers of Excellence in the Basic Biology of Aging, as well as NIH grants P30AG013280 and P30AG013319.

This patient-friendly article is based on peer-reviewed research published in Science Translational Medicine. It has been adapted to make the scientific content accessible to a general audience while preserving all key data, findings, and conclusions from the original publication.